Editas Medicine Pivots to In Vivo Gene Editing as Shares Recover from Yearly Nadir

Editas Medicine shifts focus to direct in vivo gene editing, shares climb 7.21% as EDIT-401 shows promise in cutting LDL cholesterol by 90% in primate studies.

Editas Medicine is placing a high-stakes bet on direct gene editing inside the body, a strategic about-face that has caught the attention of investors. The biotech firm's decision to jettison older approaches and concentrate resources on its in vivo platform sent the stock climbing 7.21% to €2.38 at Friday's close, extending a recovery from the year's low of €1.36 hit in February.

The shares have now advanced roughly 36% since the start of 2025, though the one-year picture shows a more modest gain of 18% — a reflection of the roller-coaster ride that has come with the company's shifting narrative. That journey is far from over. The annualized 30-day volatility hovers near 98%, underscoring just how hair-trigger the stock remains.

At the heart of the revived thesis is EDIT-401, a therapy designed to tackle lipid metabolism disorders by ramping up production of the LDLR protein. In primate studies, a single dose slashed harmful LDL cholesterol by an average of 90%. Management is now racing to move that candidate into the clinic, with initial human data expected by the end of 2026. The hope is to eventually apply the platform to other tissue types and prove that the in vivo approach can deliver on its long-touted promise.

The company's appearance at the 2026 EHA congress has put the spotlight on its competitive positioning in the gene-editing space. But the clock is ticking. Editas has enough cash on hand to fund operations only through the second quarter of 2027, giving the firm a narrow window to generate clinical proof of concept. A recent capital raising has provided some breathing room, but the pressure to show results is acute.

From a technical perspective, the stock sits in neutral territory. Friday's close of €2.38 lies just under the 50-day moving average of €2.51, while trading about 4% above the 200-day average of €2.29. The relative strength index reads 50.8, indicating neither overbought nor oversold conditions. The 52-week high of €3.56 remains a distant target, and market participants say it will take a definitive clinical milestone — something that clearly demonstrates the superiority of Editas' CRISPR platform — to close that gap.

Meanwhile, the broader CRISPR sector continues to attract fresh capital despite the inherent risks. Scribe Therapeutics recently secured $25 million for preclinical programs targeting cardiovascular and metabolic diseases, signaling that investors remain willing to fund gene-editing plays even amid the volatility. Editas, which has positioned itself as a pioneer of in vivo gene therapy, now must prove that its lead in that arena can translate into a viable commercial product.

Scientific advances are also stirring in the lab. Researchers are exploring technologies such as the "minimally evolved ABE" to reduce off-target effects, and animal models for muscular dystrophy and cancer are progressing. Whether Editas can hold its own against better-capitalized rivals will hinge on whether it can deliver the next big milestone: a clinical trial that validates its own CRISPR approach. Without that, the journey back to the year's high — and beyond — may remain elusive.